Monograph Details
|
|
Neoplasms
> Antimetabolites
|
|
TABLOID |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antimetabolite. |
| Generic Name |
|
Thioguanine 40mg; tabs; scored. |
| Indications |
|
Remission induction and remission consolidation treatment of acute nonlymphocytic leukemias. Treatment of the chronic phase of chronic myelogenous leukemia (see literature). |
| Adults and Children |
|
See literature. Initially, 2mg/kg per day. If, after 4 weeks, with no improvement, no leukocyte or platelet depression, may increase to 3mg/kg per day. Total daily dose may be given at one time. |
| Contraindications |
|
Allergy to mercaptopurine. |
| Precautions |
|
Not recommended for maintenance therapy or long-term continuous treatments; increased risk of liver toxicity (discontinue if occurs). Pre-existing liver disease. Monitor liver function tests weekly at start of therapy, then monthly thereafter. Thiopurine methyltransferase (TPMT) enzyme deficiency (may need to reduce dose to avoid severe bone marrow suppression); consider testing for TPMT deficiency. Obtain hemoglobin, hematocrit, WBCs with differential, platelets frequently during therapy. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended. |
| Interactions |
|
Avoid live vaccines (if immunocompromised). Caution with drugs that inhibit TPMT (eg, olsalazine, mesalazine, or sulphasalazine). |
| Adverse Reactions |
|
Myelosuppression, hyperuricemia, GI upset, anorexia, stomatitis, hepatotoxicity, elevated liver enzymes, jaundice (discontinue if occurs). |
| How Supplied |
|
Tabs—25 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
